Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s12883-017-0844-z http://scihub22266oqcxt.onion/10.1186/s12883-017-0844-z C5369011!5369011 !28347283     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28347283 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       BMC+Neurol 2017 ; 17 (1 ): 62 Nephropedia Template TP {{tp|p=28347283 |t=2017. Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment |pdf=|usr=}}{{28347283 }} gab.com Text Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment JO: BMC Neurol http://www.kidney.de/pget.php?&tw=1&pmid=28347283 #FOAvip BACKGROUND: Multiple sclerosis (MS) patients often suffer from gait impairment and fampridine is indicated to medically improve walking ability in this population. Patient characteristics, healthcare resource use, and costs of MS patients on fampridine treatment for 12 months in Germany were analyzed. METHODS: A retrospective claims database analysis was conducted including MS patients who initiated fampridine treatment (index date) between July 2011 and December 2013. Continuous insurance enrollment during 12 months pre- and post-index date was required, as was at least 1 additional fampridine prescription in the fourth quarter after the index date. Patient characteristics were evaluated and pre- vs post-index MS-related healthcare utilization and costs were compared. RESULTS: A total of 562 patients were included in this study. The mean (standard deviation [SD]) age was 50.5 (9.8) years and 63% were female. In the treatment period, almost every patient had at least 1 MS-related outpatient visit, 24% were hospitalized due to MS, and 79% utilized MS-specific physical therapy in addition to the fampridine treatment. Total MS-related healthcare costs were significantly higher in the fampridine treatment period than in the period prior to fampridine initiation (?17,392 vs ?10,960, P?<?0.001). While this difference was driven primarily by prescription costs, MS-related inpatient costs were lower during fampridine treatment (?1,333 vs ?1,565, P?<?0.001). CONCLUSIONS: Physical therapy is mainly used concomitant to fampridine treatment. While healthcare costs were higher during fampridine treatment compared to the pre-treatment period, inpatient costs were lower. Further research is necessary to better understand the fampridine influence. Twit Text FOAVip Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment ????BMC Neurol http://www.kidney.de/pget.php?&tw=1&pmid=28347283 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28347283 #FOAvip English Wikipedia <ref>{{Cite pmid|28347283 }}</ref> Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment #MMPMID28347283 Ziemssen T ; Prosser C ; Haas JS ; Lee A ; Braun S ; Landsman-Blumberg P ; Kempel A ; Gleißner E ; Patel S ; Huang MY BMC Neurol 2017[Mar]; 17 (1 ): 62 PMID28347283 show ga BACKGROUND: Multiple sclerosis (MS) patients often suffer from gait impairment and fampridine is indicated to medically improve walking ability in this population. Patient characteristics, healthcare resource use, and costs of MS patients on fampridine treatment for 12 months in Germany were analyzed. METHODS: A retrospective claims database analysis was conducted including MS patients who initiated fampridine treatment (index date) between July 2011 and December 2013. Continuous insurance enrollment during 12 months pre- and post-index date was required, as was at least 1 additional fampridine prescription in the fourth quarter after the index date. Patient characteristics were evaluated and pre- vs post-index MS-related healthcare utilization and costs were compared. RESULTS: A total of 562 patients were included in this study. The mean (standard deviation [SD]) age was 50.5 (9.8) years and 63% were female. In the treatment period, almost every patient had at least 1 MS-related outpatient visit, 24% were hospitalized due to MS, and 79% utilized MS-specific physical therapy in addition to the fampridine treatment. Total MS-related healthcare costs were significantly higher in the fampridine treatment period than in the period prior to fampridine initiation (?17,392 vs ?10,960, P? |4-Aminopyridine/economics/*therapeutic use [MESH] |Adult [MESH] |Female [MESH] |Germany [MESH] |Health Care Costs/*statistics & numerical data [MESH] |Humans [MESH] |Male [MESH] |Middle Aged [MESH] |Multiple Sclerosis/drug therapy/*economics/*therapy [MESH] |Patient Acceptance of Health Care/*statistics & numerical data [MESH] |Potassium Channel Blockers/economics/*therapeutic use [MESH]Healthcare resource use and costs of multiple sclerosis patients in Ge(epmc).pdf DeepDyve Pubget Overpricing